Abstract:A versatile oncolytic nanoplatform (Spi‐Mn/MoOx CPs) is designed, drawing inspiration from the delicate physicochemical structure and potent bioactivity of native oncolytic viruses. This nanoplatform effectively ameliorates tumor immune suppression and expedites the antitumor immune responses while sparing healthy tissue, thus presenting a new biomimetic idea to address conundrums in clinical oncolytic therapy. The approval of oncolytic viruses as antigen‐agnostic cancer vaccines provides a paradigm shift for immunotherapy. However, a delicate balance between safety and immunogenicity whether native or engineered oncolytic viruses remains elusive and further compounded by oncolysis‐induced immunosuppression. To address these dilemmas, the de novo design and synthesis of oncolytic viruses‐inspired nanoplatform are proposed by emulating desirable nanostructure and bioactivity for effective cancer immunotherapy. Initially, the influence of MoOx nanoparticles with varying physical morphologies on siRNA transfection are explored, wherein the virus‐inspired MoOx nanoparticles with spiky surfaces (Spi‐MoOx) are well positioned to serve as siRNA vectors to present the highest transfection efficacy. Given the preexisting immune suppression, defect engineering is incorporated into Spi‐MoOx through Mn dopants (Spi‐Mn/MoOx), in an effort to participate in tumor adaptation to hypoxia and maximize the oncolytic potency, while retaining favorable safety profiles. More importantly, the engineered oncolytic viruses hold considerable promise to function as a universal platform that enables any gene to be modulated precisely, allowing the selective activation of various pathways. Collectively, the study offers insights into the biomimetic synthesis and bioactivity of biological system through manipulating the physicochemical cues, while carrying significant implications to propel artificial oncolytic agents from the laboratory to clinical settings.

Enantiomeric Virus-Inspired Oncolytic Particles for Efficient Antitumor Immunotherapy

Physicochemical Cues Steering Spiky Mn/MoOx Nanocarriers to Mimic Oncolytic Virus for Potentiating Cancer Immunotherapy

Oncolytic Adenovirus Programmed by Synthetic Gene Circuit for Cancer Immunotherapy

Systemic Administration with Bacteria-Inspired Nanosystems for Targeted Oncolytic Therapy and Antitumor Immunomodulation

Virus-mimetic Systems for Cancer Diagnosis and Therapy.

Oncolytic Virus‐Driven Biotherapies from Bench to Bedside (Small 23/2023)

Oncolytic Viruses in Cancer Immunotherapy

Virus-like siRNA construct dynamically responsive to sequential microenvironments for potent RNA interference

Engineering Oncolytic Adenoviruses with VSVG‐Decorated Tumor Cell Membranes for Synergistically Enhanced Antitumor Therapy

Morphological and Constituent Viral-Mimicking Self-Assembled Nanoparticles Promote Cellular Uptake and Improve Cancer Therapeutic Efficiency in Vivo

Virus-inspired strategies for cancer therapy

Chiral Protein Supraparticles for Tumor Suppression and Synergistic Immunotherapy: an Enabling Strategy for Bioactive Supramolecular Chirality Construction

Bioorthogonal Engineered Virus-Like Nanoparticles for Efficient Gene Therapy

Oncolytic Adenovirus: Prospects for Cancer Immunotherapy

Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors with Low Coxsackie and Adenovirus Receptor.

The investigation of oncolytic viruses in the field of cancer therapy

[Advances in research on oncolytic adenoviruses in tumor therapy]

Engineering Oncolytic Vaccinia Virus with Functional Peptides Through Mild and Universal Strategy

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Nanoengineering-armed oncolytic viruses drive antitumor response: progress and challenges

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects